Q1 2024 Earnings Estimate for Sanofi (NASDAQ:SNY) Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs cut their Q1 2024 EPS estimates for shares of Sanofi in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn $0.94 per share for the quarter, down from their prior forecast of $0.98. The consensus estimate for Sanofi’s current full-year earnings is $4.16 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2024 earnings at $3.97 EPS, FY2025 earnings at $4.44 EPS and FY2028 earnings at $5.34 EPS.

A number of other research analysts have also issued reports on SNY. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Morgan Stanley initiated coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target for the company. Finally, TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Trading Down 1.6 %

Sanofi stock opened at $45.39 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average price of $47.52 and a two-hundred day moving average price of $48.67. The firm has a market capitalization of $114.82 billion, a price-to-earnings ratio of 19.23, a PEG ratio of 1.71 and a beta of 0.61. Sanofi has a 52-week low of $42.63 and a 52-week high of $57.82.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion.

Institutional Investors Weigh In On Sanofi

A number of large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Sanofi by 773.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock valued at $275,000 after acquiring an additional 5,004 shares during the period. Park Place Capital Corp increased its stake in Sanofi by 6.3% in the 1st quarter. Park Place Capital Corp now owns 9,068 shares of the company’s stock valued at $441,000 after buying an additional 534 shares during the period. BKM Wealth Management LLC increased its stake in Sanofi by 74.3% in the 1st quarter. BKM Wealth Management LLC now owns 8,314 shares of the company’s stock valued at $404,000 after buying an additional 3,543 shares during the period. First Bank & Trust increased its stake in Sanofi by 24.1% in the 1st quarter. First Bank & Trust now owns 35,855 shares of the company’s stock valued at $1,743,000 after buying an additional 6,968 shares during the period. Finally, Register Financial Advisors LLC acquired a new position in Sanofi in the 1st quarter valued at approximately $29,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.